Powerhouse Therapeutics Inc is a biotechnology company developing cell-based therapies that target treatment resistance in solid tumors and fibrotic diseases. Its proprietary IT-ACTS platform enables immune supercharging cell therapies, with lead candidate PH102 a GPC3-targeted therapy for hepatocellular carcinoma. The company was spun out in 2024 from the Huang Lab at UT Health San Antonio by founders Gang Huang and Vincent Pham, and is headquartered in San Antonio, Texas.